This study is to describe neurocognitive function in patients with relapsing multiple sclerosis (RMS) treated with LEMTRADA® in routine clinical practice as measured by the Multiple Sclerosis Cognitive (MS-COG) composite score. Additional neurocognitive tests will also be administered and reviewed as well as MRI data when available. The study includes a screening period of up to 30 days followed by a baseline visit, month 12 and month 24/EQS visit for a total of four visits.
Who may be Eligible
Patients with relapsing forms of MS aged 25-55 years old who are selected for treatment for treatment with Lemtrada(® and enrolled in the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program in the US are eligible for this study. The decision to treat with LEMTRADA(® will be done prior to and independent of the proposal to enroll in this study. To participate, patients must be able to give signed written informed consent.